Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Insulet Corp.
PODD
NASDAQ·Healthcare·Medical - Devices·Mkt cap $11.1B
$165.65
▲ +3.67%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$138.79 - $354.88
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 47.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Tubeless, disposable pod design eliminates tubing and provides superior patient convenience
- Proprietary wireless technology and user-friendly interface create strong brand loyalty
- Established distribution network across multiple channels in key global markets
- Patent portfolio protecting core technology and design innovations
Bear Case
2 risks
- Average volatility.
- Premium valuation to Medical Devices peers
Growth
Moderate growth ahead
Rising global diabetes prevalence and increasing adoption of insulin pump therapy
Value
Premium valuation to Medical Devices peers
Momentum
Falling
-21.8% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying PODD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 5, 2026
MAY 6, 2026
Reported EPS of $1.42 vs $1.19 consensus (+19.3% surprise). Revenue of $761.7M vs $729.9M expected (+4.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+19.3%
Next: Aug 5, 2026
Revenue trend · last 8Q
—
—
+17%
+29%
+33%
+30%
+31%
+34%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$488.5M
$543.9M
$597.5M
$569.0M
$649.1M
$706.3M
$783.8M
$761.7M
Margins · last 8Q
Gross
—
Operating
—
Profit
12.0%
Wall Street consensus
17 analysts · 82% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
82%
Hold
12%
Sell
6%
Median Price Target
$235.00
▲ +41.9% vs $165.65
Latest: Deutsche Bank · Jun 23, 2026
11 analysts covering